Activase 100 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FX4E7
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $43,151
Award facts
- Contract value 100% obligated
- $43,150.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $43,150.77 firm fixed-price delivery order to Amerisourcebergen Drug Corp for Activase 100 mg vials on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a non-set-aside competitive award to be performed at the contractor's facility in Conshohocken, Pennsylvania. Activase (alteplase) is a thrombolytic medication used in acute medical emergencies to dissolve blood clots, making it a critical pharmaceutical for military medical treatment facilities and healthcare systems. The award represents a task order under Amerisourcebergen's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.99 million through December 31, 2031, which serves as the primary vehicle for pharmaceutical and medical supply deliveries to support global military healthcare operations.
Cencora, Inc., operating as Amerisourcebergen, is a leading pharmaceutical distributor that provides an extensive range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to federal agencies. The company's federal contract portfolio demonstrates significant capability in supplying critical medications across multiple therapeutic domains to the Department of Defense healthcare system and other government entities. This delivery order is one of numerous task orders executed under the parent IDC vehicle, reflecting the contractor's established performance in meeting federal pharmaceutical procurement requirements through competitive, firm fixed-price arrangements.
Quick answers
Who was awarded contract SPE2DR26FX4E7?
SPE2DR26FX4E7 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FX4E7 worth?
The government has obligated $43,151 on SPE2DR26FX4E7.
Is contract SPE2DR26FX4E7 an order under another contract?
Yes. SPE2DR26FX4E7 is a delivery order under SPE2DR25D2218, an indefinite delivery contract.
Was contract SPE2DR26FX4E7 competed?
The extent of competition for SPE2DR26FX4E7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award